Business
Business Update and U.S. Q2 2023 Highlights
Business Update and U.S. Q2 2023 Highlights.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\n \nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nBusiness Update and U.S. Q2 2023 Highlights\n \nStrong Q2 2023 with U.S. Accrufer® Prescription Growth\nTotal U.S. prescriptions increased by 50% in 2nd quarter to 15,800, including 30% growth in June\nCompletion of commercial expansion to 100 sales representatives, refreshed brand positioning and marketing campaign launched in May\n \nLondon, UK, 20 July, 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anemia) reports a business update covering recent developments, including strong Q2 2023 U.S. Accrufer® growth.\nThe Company saw strong prescription growth in Q2 and 1H 2023. Total prescriptions for the 2nd quarter of 2023 increased to over 15,800, a 50% increase compared to Q1 2023, and a 173% rise compared to the same period in 2022. In the first half of 2023, total prescriptions grew to approximately 26,300 which exceeds the total prescription volume for all of 2022 and represents an increase of 210% compared to 1H 2022.\nThe substantial growth in H1 puts Shield on track to meet its 2023 Goal for U.S. Accrufer® prescriptions:\nSnapshot of increasing Q2 KPI metrics - (all comparisons are sequential to Q1 2023)\n· Increase in total prescriptions -- Over 15,800, grew 50%\no May grew 28% vs April, and June grew 30% vs May\n· Increase in new prescriptions - grew 63%\n· Increase in first time writers - grew 157%\n· Positive clinical experiences leading to follow-up prescriptions\no High percentage of repeat writers - 73% of the HCP's who wrote an Rx in Q1 '23 wrote another prescription in Q2\n \nSubstantial market opportunity: As the first and only FDA approved oral iron to treat ID/IDA with a broad label, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.\n \nKey drivers in making Accrufer® the oral iron treatment of choice in the U.S. include:\n· Shield/Viatris commercial expansion, completed in May - Bui...